Takeda Pharmaceutical Co., Japan’s largest drugmaker, expects a 55 percent decline in profit this year from costs related to the $8.8 billion takeover of Millennium Pharmaceutical Inc. last month.
Net income will fall to ¥160 billion for the year ending next March 31, the firm said Friday in a statement to the Tokyo Stock Exchange.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.